Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.

@article{Rennard2001UseOA,
  title={Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.},
  author={Stephen I. Rennard and W. French Anderson and Richard L Zuwallack and John Broughton and William Bailey and Max Friedman and Marek Wiśniewski and Kathleen Rickard},
  journal={American journal of respiratory and critical care medicine},
  year={2001},
  volume={163 5},
  pages={1087-92}
}
Chronic obstructive pulmonary disease (COPD) is a condition in which continuous bronchodilation may have clinical advantages. This study evaluated salmeterol, a beta-agonist bronchodilator with a duration of action substantially longer than that of short-acting beta-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD. Four hundred and five patients with COPD received either salmeterol 42 microg twice daily, ipratropium bromide 36 microg four… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 83 extracted citations

Similar Papers

Loading similar papers…